

# Accepted Manuscript

Title: Body composition evaluated by body mass index and bioelectrical impedance vectorial analysis in women with rheumatoid arthritis

Author: Juan Antonio Pineda-Juárez, Mariel Lozada-Mellado, Midori Ogata-Medel, Andrea Hinojosa-Azaola, Cira Santillán-Díaz, Luis Llorente, Arturo Orea-Tejeda, Jorge Alcocer-Varela, Rolando Espinosa-Morales, Marco González-Contreras, Lilia Castillo-Martínez



PII: S0899-9007(18)30016-9  
DOI: <https://doi.org/10.1016/j.nut.2018.01.004>  
Reference: NUT 10110

To appear in: *Nutrition*

Received date: 7-2-2017  
Revised date: 7-8-2017  
Accepted date: 22-1-2018

Please cite this article as: Juan Antonio Pineda-Juárez, Mariel Lozada-Mellado, Midori Ogata-Medel, Andrea Hinojosa-Azaola, Cira Santillán-Díaz, Luis Llorente, Arturo Orea-Tejeda, Jorge Alcocer-Varela, Rolando Espinosa-Morales, Marco González-Contreras, Lilia Castillo-Martínez, Body composition evaluated by body mass index and bioelectrical impedance vectorial analysis in women with rheumatoid arthritis, *Nutrition* (2018), <https://doi.org/10.1016/j.nut.2018.01.004>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1           **Body composition evaluated by body mass index and bioelectrical**  
2           **impedance vectorial analysis in women with rheumatoid arthritis**

3  
4    Juan Antonio Pineda-Juárez, MSc<sup>1</sup>

5    Mariel Lozada-Mellado, MSc<sup>1</sup>

6    Midori Ogata-Medel, BSc<sup>1</sup>

7    Andrea Hinojosa-Azaola, MD, MSc<sup>2</sup>

8    Cira Santillán-Díaz, MSc<sup>3</sup>

9    Luis Llorente, MD<sup>2</sup>

10   Arturo Orea-Tejeda, MD<sup>4</sup>

11   Jorge Alcocer-Varela, MD, PhD<sup>2</sup>

12   Rolando Espinosa-Morales, MD<sup>3</sup>

13   Marco González-Contreras, MD<sup>2</sup>

14   Lilia Castillo-Martínez, PhD<sup>1</sup>

15

16   Departments of Clinical Nutrition<sup>1</sup> and Immunology and Rheumatology<sup>2</sup> Instituto Nacional  
17   de Ciencias Médicas y Nutrición Salvador Zubirán, Rheumatology Service, Instituto  
18   Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra<sup>3</sup>, and Instituto Nacional de  
19   Enfermedades Respiratorias Ismael Cosío Villegas<sup>4</sup>

20

21   \*Corresponding author: Lilia Castillo Martínez. Address: Vasco de Quiroga 15, Tlalpan,  
22   Sección XVI, CP 14000 Mexico D.F. e-mail: caml1225@yahoo.com

23

24   **Data Analysis and Responsibility:**

25   JAPJ, MLM was responsible for the conception and design of the study; generation,  
26   collection, and interpretation of data; and drafting the manuscript. LCM, CSD, LL, AOT  
27   were responsible for generation of data and revision of the manuscript. AHA, JAV, REM,  
28   MGC were responsible for analysis and interpretation of the data and revision of the  
29   manuscript. All authors approved the final version of the manuscript. The authors declare  
30   no conflicts of interest.

## 31 Highlights

32

33 1. Patients with rheumatoid arthritis with normal or high BMI have a  
34 significantly lower muscle component.

35 2. The frequency of cachexia detected by BIVA in patients with arthritis  
36 rheumatoid was higher

37 3. Lower phase angle could be an indicator of a worse prognosis during  
38 disease course in rheumatoid arthritis.

39 4. BIVA method in rheumatoid arthritis patients could be a suitable option for  
40 cachexia detection.

41

42

43

## 44 Abstract

45

46 **Background:** Rheumatoid arthritis (RA) is a complex inflammatory disease that  
47 modifies body composition. Although body mass index (BMI) is one of the clinical  
48 nutrition tools widely used to assess indirectly nutritional status, it is not able to  
49 identify these body alterations. Bioelectrical Vector Analysis (BIVA) is an  
50 alternative method to assess hydration and body cell mass of patients with wasting  
51 conditions. **Objective:** To investigate the differences in nutrition status according to  
52 BMI groups (normal, overweight and obesity) and BIVA classification (cachectic  
53 and non-cachectic) in women with RA. **Methods:** Women with confirmed diagnosis  
54 of RA were included from January 2015 to June 2016. Whole-body bioelectrical  
55 impedance was measured using a tetrapolar and mono-frequency equipment.  
56 Patients were classified according to BMI as: low body weight (n=6, 2.7%), normal  
57 (n=59, 26.3%), overweight (n=88, 39.3%) and obese (n=71, 31.7%), and each  
58 group was divided into BIVA groups (cachectic 51.8% and non-cachectic 48.2%).  
59 **Results:** A total of 224 RA patients were included, with mean age 52.7 years and  
60 median disease duration of 12 years. Significant differences were found in weight,  
61 arm circumference, waist, hip, resistance/height, reactance/height and erythrocyte  
62 sedimentation rate among all BMI groups. However, serum albumin levels were  
63 significantly different between cachectic and non-cachectic patients independently

64 of BMI. In all BMI categories, cachectic groups had lower reactance and phase  
65 angle than non-cachectic subjects. **Conclusion:** RA patients with normal or even  
66 high BMI have a significantly lower muscle component. Evaluation of body  
67 composition with BIVA in RA patients could be an option for cachexia detection.

68

69 **Keywords:** rheumatoid arthritis, bioelectrical impedance vector analysis, body  
70 mass index, body composition; nutritional status

71

## 72 **Introduction**

73 Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by  
74 inflammation, joint pain, and destruction of the synovial membranes [1]. Life  
75 expectancy of these patients can be reduced by an average of 3 to 18 years and  
76 80% are disabled after 20 years [2, 3]. Metabolic alterations in RA due mainly to  
77 the liberation of tumor necrosis factor alpha and interleukin-1 beta can lead to  
78 rheumatoid cachexia, which is defined as “the involuntary loss of fat free mass  
79 (FFM) with minimal or not weight loss and increase or not of fat mass (FM)” which  
80 causes muscular weakness and loss of functional capacity. Also, the mean loss of  
81 FFM, present in almost two thirds of patients with RA, is between 13 and 15%. [4].

82 In clinical nutrition practice, a widely-employed tool used to evaluate body  
83 mass and hence nutritional status is the body mass index (BMI). However, its main  
84 limitation is that is not able to identify rheumatoid cachexia alterations such as loss  
85 of FFM and gain of FM [5].

86 Several imaging techniques have been used to analyze body composition in  
87 RA patients. Currently, the most useful tool for measuring soft tissue mass and  
88 bone mineral density is dual X-ray absorptiometry (DXA) [6, 7]. Nevertheless, DXA  
89 is not always accessible and is sensitive to the patient's hydration status [8] and  
90 also is associated with radiation exposure [9]. Therefore, a simple tool for  
91 identifying body composition alterations as rheumatoid cachexia in outpatient  
92 settings is necessary [10].

93 Bioelectrical impedance analysis (BIA) is easy to operate, portable, and has  
94 a relatively low cost. Additionally, it has been reported as one of the most  
95 commonly used methods to estimate body composition using prediction equations,  
96 taking into account impedance parameters and reactance [11, 12]. However,  
97 homogenous composition, fixed cross-sectional area and consistent distribution of  
98 current density are necessary assumptions for the correct estimation of body  
99 composition [12]. These conditions are frequently violated in sick and hospitalized  
100 patients since disturbed fluid status or altered distribution of extra- and intra-cellular  
101 water are often present [12]. For example, if an individual is hyperhydrated, the  
102 FFM value is overestimated [13].

103 Bioelectrical impedance vector analysis (BIVA or vector BIA) is an  
104 alternative method that overcomes the need of assumptions for conventional BIA  
105 because it determines the resistance (R) and the reactance (Xc) obtained at 50  
106 kHz, which are normalized with the subject's height (R/H and Xc/H) and then  
107 plotted as random vectors (points) on the R-Xc graph (R/H in X axis and Xc/H in Y  
108 axis) [11, 12, 14]. Impedance vector of an individual patient can be plotted in  
109 confidence ellipses drawn from a healthy reference population; normal individuals  
110 fall within the reference 75% tolerance ellipse. Wasting conditions (e.g., cancer,  
111 heart failure, and anorexia nervosa) have been associated with a displacement  
112 downward and to the right along the minor axis in the middle regions of the RXc  
113 graph [11].

114 Evaluation of nutritional status by BIVA method in RA patients has not been  
115 reported in the literature. Therefore, the aim of the present study to investigate the  
116 differences in nutrition status according to BMI groups (normal, overweight and  
117 obesity) and BIVA classification (cachectic and non-cachectic) in women with RA.

118

## 119 **Material and methods**

### 120 ***Study population***

121 A total of 224 patients with RA were consecutively recruited from January

122 2015 to June 2016 at two of the National Health Institutes in Mexico City, Mexico:  
123 Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ)  
124 and Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra (INR). All  
125 patients were ambulatory and attended at the Immunology and Rheumatology  
126 Clinic at their respective Institute. The study protocol was approved by the ethics  
127 and investigation in human's committee of both Institutes and an informed consent  
128 was obtained from all participants. Female patients, >18 years of age, with a  
129 confirmed diagnosis of RA according to the American College of Rheumatology  
130 (ACR)/European League against Rheumatism (EULAR) 2010 criteria were  
131 included [1]. Patients with end-stage renal disease, uncontrolled dysthyroidism,  
132 hepatic failure and cancer or other autoimmune disease overlapping were  
133 excluded to avoid confusion related to changes in body composition.

134

135 Three Rheumatologists (AHA, REM, MGC) blinded to the body composition  
136 data evaluated all patients. Information regarding comorbidities (e.g. arterial  
137 hypertension, diabetes mellitus and dyslipidemia), disease duration and treatment  
138 was obtained. Disease activity was assessed using the Disease Activity Score  
139 (DAS28) [15], a clinical index of RA disease activity that combines information from  
140 swollen joints, tender joints, as well as acute phase response and general health.  
141 According to this index, the level of disease activity is considered low (<3.2),  
142 moderate (3.2-5.1), or high (>5.1). Pain was evaluated with a Visual Analogue  
143 Scale (VAS), ranging from 1 to 10, while global functional status was assessed in  
144 classes I-IV. [16].

145 Venous blood samples were drawn from patients after an overnight fast for  
146 determination of high sensitive C-reactive protein (CRP), erythrocyte sedimentation  
147 rate (ESR), lymphocytes, hemoglobin, hematocrit and albumin. All laboratory tests  
148 were determined using routine automated analyzers. Serum albumin levels were  
149 determined using the bromocresol green albumin method.

150 *Anthropometry*

151 Weight and height were measured according to the standard anthropometric  
152 method [17], while body mass index (BMI) was calculated using the formula that  
153 divides the body weight in kilograms by the height squared in meters. Patients  
154 were classified as normal (18.5-24.9), overweight (25-29.9) or obesity (>30) [18]. A  
155 qualified Nutritionist (JAPJ, MLM, MOM) performed all measurements.

156

#### 157 *Bioelectrical impedance analysis (BIA)*

158 Whole-body bioelectrical impedance was measured using a tetrapolar and  
159 mono-frequency equipment (RJL Quantum X, RJL Systems; Michigan, USA). All  
160 measurements were performed according to the reported technique [19]. Patients  
161 removed all metallic objects that were in contact with the skin to avoid erroneous  
162 measurements; they were in fasting conditions for at least 8 hours and avoided  
163 vigorous physical activities or alcohol intake in the previous 24-hours. During the  
164 procedure, patients were placed in decubitus position with arms apart 30 cm from  
165 the body and legs apart 50 cm from each other. In the case of obese patients (if  
166 necessary), a towel was placed between the thighs to avoid the contact and  
167 prevent poor conductivity. The impedance values were obtained at 50 kHz  
168 frequency: resistance (R), reactance (Xc) and the phase angle (PA). PA was  
169 obtained by a previous predictive formula [20].

170

#### 171 *Bioelectrical impedance vector analysis (BIVA)*

172 The data obtained by BIA (R and Xc) were standardized in accordance with  
173 the height of each patient in order to obtain the impedance vector, which is  
174 represented in the RXc graph [11, 23]. The R-Xc graph used was the Mexican  
175 reference of healthy population [21-23].

176

177 The gender-specific RXc graph was divided into 2 sectors. Patients with  
178 vectors out of the 75% tolerance ellipse of the reference population at the right side  
179 of the RXc-graph were classified as cachectic and as overhydration those patients

180 with vectors below of the 75% tolerance ellipse of the reference population on the  
181 longitudinal axis of the RXc-graph. [21-24]

182

### 183 ***Statistical analysis***

184 The Kolmogorov-Smirnov test was used to confirm if the data had a normal  
185 distribution. Continuous variables with normal distribution are presented as mean  $\pm$   
186 standard deviation, otherwise the data are presented as median and 25-75  
187 percentiles. Categorical variables are presented as frequencies and percentages.  
188 The differences among the BMI groups (normal, overweight and obesity), and  
189 BIVA groups (cachectic and non-cachectic), were assessed using two-way  
190 analysis of covariance, with age as a covariable. Hotelling's T2 test was used to  
191 compare mean BIVA vectors of BMI groups divided by cachectic and non-  
192 cachectic subjects. A p value  $<0.05$  was considered statistically significant.  
193 Analyses were performed using a commercially available package (IBM SPSS  
194 Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp) and the BIVA  
195 Software 2002 (Piccoli A. and Pastori G., Department of Medical and Surgical  
196 Sciences, University of Padova, Padova, Italy, 2002).

197

### 198 **Results**

199 Two hundred and twenty four female patients with RA were included, with a  
200 mean age of 52.7 years and median disease duration of 12 years. The most  
201 frequent comorbidity was hypertension (27.3%), followed by dyslipidemia (14.1%)  
202 and diabetes (12.8%). Most of the patients had low disease activity (mean  
203 DAS28=3.1), and 37% were in functional class I. According to the VAS most  
204 patients had moderate pain (median VAS=6). The most frequent disease-modifying  
205 antirheumatic drugs were methotrexate (63.4%), sulfasalazine (33.5%), and  
206 antimalarials (30.8%), while glucocorticoids were used in 22.7% and leflunomide in  
207 12.3%. These data are summarized in Table 1.

208 According to BMI groups, six patients (2.7%) had low body weight (not  
209 included in the analysis of Table 2); 59 (26.3%) were normal; 88 (39.3%) had  
210 overweight and 71 (31.7) had obesity. In accordance to BIVA, 116 (51.8%) were  
211 classified as cachectic and non-cachectic 108 (48.2%); and 47 (21%) with  
212 overhydration.

213 Table 2 shows comparisons of anthropometric, parameters of bioelectrical  
214 impedance analysis, albumin, CRP and ESR parameters between BMI categories  
215 divided by cachectic and non-cachectic subjects. Statistically significant differences  
216 were found in weight, arm, waist and hip circumferences, R/H and Xc/H between  
217 all BMI groups. In all BMI categories, cachectic groups had lower reactance and  
218 phase angle than non-cachectic subjects. When we compared the cachectic and  
219 non-cachectic group within each BMI category, we observed significant differences  
220 in arm circumference, R/H, Xc/H, phase angle and albumin levels. All cachectic  
221 subjects independently of BMI group had lower levels of serum albumin.

222 Figure 1 shows mean R/H and XC/H, where the values between non-cachectic  
223 subjects (1, 3 and 5) are very similar. However, mean R/H was higher in the  
224 cachectic groups of normal (2) and overweight BMI (4) while the cachectic group of  
225 obese BMI (6) showed lower R/H in comparison with the other two cachectic  
226 groups. In all BMI categories, cachectic groups had lower Xc/H and phase angle  
227 than each one of their non-cachectic counterparts, being all the differences  
228 statistically significant.

## 229 Discussion

230 In the present study, we observed that although patients were classified as normal,  
231 overweight or obese according to their BMI, BIVA detected cachectic patients  
232 within all BMI categories. In addition, serum albumin levels were lower in cachectic  
233 subjects independently of BMI categories; this could be explained because  
234 hypoalbuminemia is a consequence of inflammation due to suppression of albumin  
235 synthesis and transfer of albumin from the vascular to the extravascular space.  
236 Moreover, patients with RA have increased whole-body protein breakdown

237 associated with higher TNF- $\alpha$  levels. It has been reported that in patients with RA,  
238 serum albumin is lower than in controls, and statistically associated with RA  
239 functional class, while a negative correlation exists with clinical, functional, and  
240 laboratory markers of disease activity [25].

241 Our results are similar to previous descriptions. Van Bokhorst-de van der Schueren  
242 et al reported high prevalence of overweight and obesity in RA patients, in  
243 combination with a reduced FFM and an increase of the FM. This explains why  
244 despite their classification as normal weight, overweight or obese, cachectic  
245 patients can be detected by the BIVA method [26].

246 Elkan et al evaluated body composition by DXA and found that 52% of women and  
247 30% of men with RA were malnourished according to FFM determined by this  
248 method even if they were classified as normal, overweight or obese by BMI. Thus,  
249 the authors concluded that neither the BMI nor the nutritional assessment and  
250 screening tools could detect the low FFM with sufficient sensitivity and specificity to  
251 be used to assess cachexia [27]. Also, Konijn et al studied the differences between  
252 BMI and BIA and found that 44% of the studied women with a normal BMI had low  
253 FFM and 75% of men and 40% women had high FM. [5] These results are similar  
254 to our findings, demonstrating the low value of the BMI measurement in RA  
255 patients [27] because is only able to reflect abundance of adipose tissue in very  
256 high BMI or a reduction of fat and lean mass in very low BMIs. The problem of  
257 sarcopenic obesity, which can occur in RA, is most certainly not reflected by the  
258 BMI.

259 The phase angle (PA) is the most widely used BIA impedance parameter [31], has  
260 been suggested to be an indicator of cellular health, where higher values reflect  
261 higher cellularity, cell membrane integrity and better cell function. PA correlates  
262 with nutritional status and it has shown to be highly predictive of impaired clinical  
263 outcome and mortality in a variety of diseases [12]. PA expresses changes in the  
264 quantity and quality of soft tissue mass [28]. There are, to our knowledge, no  
265 previous studies regarding PA in patients with RA. However, there is evidence that  
266 it is related with nutritional status, disease progression and patient prognosis in

267 heart failure patients. [29]. Considering that heart failure is characterized by a state  
268 of chronic inflammation and a hypercatabolic state, similar to RA, [30] we could  
269 hypothesize that lower PA in the cachectic patients is an indicator of a worse  
270 prognosis during disease course in RA.

271 Our study has certain limitations. First, patients had longstanding disease (median  
272 of 12 years), which could lead to a higher prevalence of cachexia. Studying  
273 patients with recent-onset RA and over time could be of interest to clarify the effect  
274 of disease duration on body composition. Second, the effect of the treatment on  
275 body composition could not be evaluated in the present study. The beneficial  
276 properties of antimalarials on metabolism are well known (reduced incidence of  
277 diabetes, reduced serum glucose, improved lipid profile and attenuation in  
278 atherosclerosis progression). Third, although patients with RA are treated with low  
279 doses of steroids, 23% of our population was receiving them and this should be  
280 considered due to the long-term effects of these compounds on fat mass.

281 In conclusion, RA patients with normal or even high BMI have a significantly lower  
282 muscle component. Evaluation of nutritional status with BIVA in RA patients could  
283 be a suitable option for cachexia detection and provide early intervention to  
284 improve body composition.

285

## 286 **Acknowledgments**

287 The authors would like to thank Professors Piccoli A and Pastori from Department  
288 of Medical and Surgical Sciences, University of Padova, Padova, Italy, 2002 for  
289 providing the BIVA software (available at e-mail: [apiccoli@unipd.it](mailto:apiccoli@unipd.it)), and Angeles  
290 Espinosa for providing the data of Mexican reference population for tolerance  
291 ellipses.

292

## 293 **Conflict of interest**

294 All authors state no conflict of interest

295

296 **References**

- 297 1. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham OC,  
298 Birnbaum NS, et al. Rheumatoid Arthritis Classification Criteria: An  
299 American College of Rheumatology/European League Against Rheumatism  
300 Collaborative Initiative. *Arthritis Rheum* 2010;62:2569-2581.
- 301 2. Pincus T, Callahan LF. Taking mortality in rheumatoid arthritis seriously-  
302 predictive markers, socioeconomic status and comorbidity. *J Rheumatol*  
303 1986;13:841-845.
- 304 3. Scott DL, Symmons DP, Coulton BL, Popert AJ. Long-term outcome of  
305 treating rheumatoid arthritis: results after 20 years. *Lancet* 1987;1:1108-  
306 1111.
- 307 4. Walsmith, J, Roubenoff R. Cachexia in rheumatoid arthritis. *Int J Cardiol*  
308 2002;85:89-99.
- 309 5. Konijn NP, Van Tuyl LH, Bultink IE, Lems WF, Earthman CP, Van Bokhorst-  
310 de van der Schueren MA. Making the invisible visible: bioelectrical  
311 impedance analysis demonstrates unfavourable body composition in  
312 rheumatoid arthritis patients in clinical practice. *Scand J Rheumatol*  
313 2014;43:273-78.
- 314 6. Summers GD, Deighton CM, Rennie MJ, Booth AH. Rheumatoid cachexia:  
315 a clinical perspective. *Rheumatology (Oxford)* 2008;47:1124-1131.
- 316 7. Tanner SB, Moore CF Jr. A review of the use of dual-energy X-ray  
317 absorptiometry (DXA) in rheumatology. *Open Acces Rheumatol.* 2012;4:99-  
318 107.
- 319 8. Kyle UG, Genton L, Hans D, Karsegard L, Slosman DO, Pichard C. Age-  
320 related differences in fat-free mass, skeletal muscle, body cell mass and fat  
321 mass between 18 and 94 years. *Eur J Clin Nutr* 2001;55:663-72.
- 322 9. Damilakis J, Adams JE, Gunglielmi G, Link TM. Radiation exposure in X-  
323 ray-based imaging techniques used in osteoporosis. *Eur Radiol.*  
324 2010;20(11):2707-2714.

- 325 10. Ellis KJ. Human body composition: in vivo methods. *Physiol Rev*  
326 2000;80:649-80.
- 327 11. Piccoli A, Nescolarde LD, Rosell J. Análisis convencional y vectorial de  
328 bioimpedancia en la práctica clínica. *Nefrología XXII* 2002;3: 228-238.
- 329 12. Norman K, Stobäus N, Pirlich M, Bosy-Westphal A. Bioelectrical phase  
330 angle and impedance vector analysis-clinical relevance and applicability of  
331 impedance parameters. *Clin Nutr.* 2012;31(6):854-61.
- 332 13. Mialich MS, Sicchieri JMF, Jordao-Junior AA. Analysis of body composition:  
333 a critical review of the use of bioelectrical impedance analysis. *International*  
334 *Journal of Clinical Nutrition* 2014;2:1-10.
- 335 14. Barbosa-Silva MC, Barros AJ. Bioelectrical impedance analysis in clinical  
336 practice: a new perspective on its use beyond body composition equations.  
337 *Curr Opin Clin Nutr Metab Care* 2005;8:311-317.
- 338 15. Fransen J and van Riel P. The Disease Activity Score and the EULAR  
339 response criteria. *Clin Exp Rheumatol* 2005; 23(Suppl. 39):S93-S99.
- 340 16. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The  
341 American College of Rheumatology 1991 Revised Criteria for the  
342 classification of global functional status in Rheumatoid Arthritis. *Arthritis*  
343 *Rheum* 1992;35:498-502.
- 344 17. Lohman TG, Roche AF, Martorell R. Anthropometric standardization  
345 reference manual. Champaign, IL: Human Kinetics; 1991:96.
- 346 18. World Health Organization. Obesity: preventing and managing the global  
347 epidemic. Report of a World Health Organization Consultation. Geneva:  
348 World Health Organization, WHO Obesity Technical Report Series 894;  
349 2000:6-15.
- 350 19. Lukaski HC, Johnson PE, Bolonchuk WW, Lykken GI. Assessment of fat-  
351 free mass using bioelectrical impedance measurements of the human body.  
352 *Am J Clin Nutr* 1985;41:810-817.

- 353 20. Kyle U, Genton L, Pichard C. Low phase angle determined by bioelectrical  
354 impedance analysis is associated with malnutrition and nutritional risk at  
355 hospital admission. *Clin Nutr* 2013;32:294-299.
- 356 21. Piccoli A, Rossi B, Pillon L, Bucciante G. A new method for monitoring body  
357 fluid variation by bioimpedance analysis: the RXc graph. *Kidney Int*  
358 1994;46:534-9.
- 359 22. Espinosa MA, Rivas L, González EC, Atilano X, Miranda P, Correa- Rolter  
360 R. Vectores de impedancia bioeléctrica para la composición corporal en  
361 población mexicana. *Rev Invest Clin* 2007;59:15-24.
- 362 23. Piccoli A, Pillon L, Dumler F. Impedance vector distribution by sex, race,  
363 body mass index, and age in the United States: standard reference intervals  
364 as bivariate Z scores. *Nutrition* 2002;18:153-67.
- 365 24. Toso S, Piccoli A, Gusella M, Menon D, Crepaldi G, Bononi A, et al.  
366 Bioimpedance vector pattern in cancer patients without disease versus  
367 locally advanced or disseminated disease. *Nutrition* 2003;19:510-514.
- 368 25. Targońska- Stepniak B, Majdan M. Associations between parameters of  
369 nutritional status and disease activity in patients with rheumatoid arthritis.  
370 *Pol Arch Med Wewn* 2011;121:122-128.
- 371 26. Van Bokhorst-de van der Schueren MA, Konijn NP, Bultink IE, Lems WF,  
372 Earthman CP, van Tuyl LH. Relevance of the new pre-cachexia and  
373 cachexia definitions for patients with rheumatoid arthritis. *Clin Nutr*  
374 2012;31:1008-10.
- 375 27. Elkan AC, Engvall IL, Tengstrand B, Cederholm T, Hafstrom I. Malnutrition  
376 in women with rheumatoid arthritis is not revealed by clinical  
377 anthropometrical measurements or nutritional evaluation tools. *Eur J Clin*  
378 *Nutr* 2008;62:1239-1247.
- 379 28. Barbosa-Silva MCG, Barros AJD, Wang J, Heymsfield SB, Pierson RN.  
380 Bioelectrical impedance analysis: population reference values for phase  
381 angle by age and sex. *Am J Clin Nutr* 2005;82:49-52.

- 382 29. Colín-Ramírez E, Castillo-Martínez L, Orea-Tejeda A, Vázquez-Durán M,  
383 Rodríguez AE, Keirns-Davis C. Bioelectrical impedance phase angle as a  
384 prognostic marker in chronic heart failure. *Nutrition* 2012;28:901-905.
- 385 30. Meek IL, Vonkeman HE, van de Laar MA. Cardiovascular case fatality in  
386 rheumatoid arthritis is decreasing; first prospective analysis of a current low  
387 disease activity rheumatoid arthritis cohort and review of the literature. *BMC*  
388 *Musculoskeletal Disorders* 2014;15:142  
389

Accepted Manuscript

390 **Table 1.** Select characteristics of study population

391

392

393

394

395

396

397

398

399

400

401

402

Accepted Manuscript

Variable	n=224
Age (years)	52.7 ± 14.2
Disease duration (years)	12 (6-19)
Body Mass Index (kg/m <sup>2</sup> )	27.5± 4.8
DAS28	3.1 ± 1.4
Pain (VAS)	6 (3.2-8.0)
CRP (mg/dL)	1.9 (0.5-6.9)
ESR (mm/hr)	24.5 (13-36)
Lymphocytes (%)	22.4 ± 10
Albumin (g/dL)	4.0 ± 0.5
Hemoglobin (g/dL)	13.7 (12.7-14.6)
Hematocrit (%)	41 (38.2-43.7)
Hypertension, n (%)	62 (27.3)
Diabetes, n (%)	29 (12.8)
Dyslipidemia, n (%)	32 (14.1)
Methotrexate, n (%)	144 (63.4)
Sulfasalazine, n (%)	76 (33.5)
Antimalarials, n (%)	69 (30.8)
Glucocorticoids, n (%)	51 (22.7)
Leflunomide, n (%)	28 (12.3)


DAS: disease activity score, VAS: visual analogue scale, ACR: American College of Rheumatology, CRP: C-reactive protein, ESR: erythrocyte sedimentation rate. Categorical variables are presented as absolute and relative frequencies and continuous variables are presented as mean ± standard deviation or median (p25 - p75).

**Table 2.** Body mass index classification according to rheumatoid cachexia

Variable	Body Mass Index Classification							
	Normal		Overweight		Obese		p between cachectic and non- cachectic	p between BMI classification
	Non-cachectic n=23	Cachectic n=36	Non-Cachectic n=48	Cachectic n=40	Non-Cachectic n=37	Cachectic n=34		
Age (years)	47.5 ± 13.8	55.3 ± 17.6	50 ± 14.2	56.3 ± 13.6	51.1 ± 11.4	55.9 ± 11.6	0.53	0.57
<b>Anthropometric</b>								
Weight (Kg)	57.4 ± 4.3	50.1 ± 7.3	65.2 ± 6.3	63.9 ± 7.0	74.5 ± 5.3	79.5 ± 10.6	0.8	<0.0001*
Arm Circumference (cm)	27.4 ± 1.4	24.8 ± 2	28.9 ± 2.7	27.7 ± 2.1	32.5 ± 1.9	32.8 ± 3.7	0.005	<0.0001
Waist (cm)	81.5 ± 11.4	78.1 ± 7.2	89.7 ± 5.5	87.8 ± 7.2	99.7 ± 5.7	103.6 ± 10.4	0.9	<0.0001
Hip (cm)	96.1 ± 3.7	92.8 ± 5.7	101.9 ± 5.1	101.7 ± 5.3	109 ± 5.8	114.5 ± 10.2	0.4	<0.0001
<b>Bioimpedance parameters</b>								
R/H	382.5 ± 30.7	474.2 ± 86.8	369.5 ± 33	398.5 ± 63.6	364.5 ± 27.5	326.4 ± 59.4	0.001	<0.0001*
Xc/H	39.6 ± 5.8	39 ± 8.9	40.0 ± 6.5	35.0 ± 10.4	41 ± 6.4	29 ± 4.9	<0.0001	0.02
Phase Angle (°)	5.9 ± 0.8	4.8 ± 1.1	6.2 ± 1.0	5.1 ± 1.4	6.4 ± 0.9	5.3 ± 1.1	<0.001	0.012
<b>Biochemical</b>								
Albumin (g/dL)	4.2 ± 0.3	3.7 ± 0.6	4.2 ± 0.2	3.8 ± 0.6	4.1 ± 0.4	3.9 ± 0.3	0.008	0.7
CRP (mg/dL)	1.1 (0.4 – 4.4)	1.5 (0.8 – 3.3)	1.4 (0.3 – 4.7)	1.1 (0.1 – 4.6)	2.1 (0.4 – 6.9)	0.9 (0.3 – 8)	0.56	0.76
ESR (mm/H)	26 (12.5 – 37.5)	22 (11 – 36)	20.5 (10 – 30.2)	34 (28 – 53)	26 (13 – 35)	25.5 (15 – 42)	0.21	0.83

R/H: resistance/height, Xc/H: reactance/height, CRP: C-reactive protein, ESR: erythrocyte sedimentation rate; continuous variables are presented as mean ± standard deviation; \*p<0.05 for interaction

**Figure 1. Mean R/H and XC/H of BMI categories and the presence or not of cachexia**



Group	Hotelling's $T^2$ Test	Mahalanobis D	p
Normal BMI non-cachectic (1) vs Normal BMI cachectic (2)	32.8	1.53	<0.00001
Overweight BMI non-cachectic (3) vs Overweight BMI cachectic (4)	27.1	1.11	<0.00001
Obese BMI non-cachectic (5) vs Obese BMI cachectic (6)	42.4	1.55	<0.00001

**Abbreviations.** BMI: body mass index